About Curis, Inc.
https://www.curis.comCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
CEO
James E. Dentzer
Compensation Summary
(Year 2021)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-29 | Reverse | 1:20 |
| 2018-05-30 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLEICHROEDER LP
Shares:1.14M
Value:$1.03M
ARMISTICE CAPITAL, LLC
Shares:978.19K
Value:$884.77K
CITIGROUP INC
Shares:581.12K
Value:$525.62K
Summary
Showing Top 3 of 53
About Curis, Inc.
https://www.curis.comCuris, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $3.18M ▲ | $10.09M ▼ | $-7.73M ▲ | -243.36% ▲ | $-0.49 ▲ | $-7.69M ▲ |
| Q2-2025 | $2.75M ▲ | $10.98M ▼ | $-8.59M ▲ | -312.59% ▲ | $-0.68 ▲ | $-8.21M ▲ |
| Q1-2025 | $2.38M ▼ | $12.52M ▲ | $-10.62M ▼ | -446.05% ▼ | $-1.25 | $-10.1M ▼ |
| Q4-2024 | $3.35M ▲ | $12.32M ▼ | $-9.62M ▲ | -287.53% ▲ | $-1.25 ▲ | $-7.21M ▲ |
| Q3-2024 | $2.93M | $13.48M | $-10.09M | -344.32% | $-1.7 | $-10.51M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $9.05M ▼ | $27.64M ▼ | $42.33M ▼ | $-14.69M ▼ |
| Q2-2025 | $10.14M ▼ | $29.23M ▼ | $43.22M ▼ | $-13.99M ▼ |
| Q1-2025 | $20.28M ▲ | $39.33M ▼ | $45.93M ▼ | $-6.61M ▼ |
| Q4-2024 | $20M ▼ | $41.27M ▼ | $47.26M ▼ | $-6M ▲ |
| Q3-2024 | $20.85M | $42.47M | $51.21M | $-8.73M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.73M ▲ | $-5.57M ▲ | $0 | $4.48M ▲ | $-1.09M ▲ | $-5.57M ▲ |
| Q2-2025 | $-8.59M ▲ | $-8.01M ▼ | $0 | $-2.13M ▼ | $-10.14M ▼ | $-8.01M ▼ |
| Q1-2025 | $-10.62M ▼ | $-7.25M ▲ | $0 ▲ | $7.54M ▼ | $285K ▲ | $-7.25M ▲ |
| Q4-2024 | $-9.62M ▲ | $-9.26M ▼ | $-428K ▼ | $8.83M ▲ | $-857K ▼ | $-9.26M ▼ |
| Q3-2024 | $-10.09M | $-5.94M | $18.32M | $-1.52M | $10.86M | $-5.94M |
Revenue by Products
| Product | Q4-2023 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Gross Royalty Revenue | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
James E. Dentzer
Compensation Summary
(Year 2021)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-09-29 | Reverse | 1:20 |
| 2018-05-30 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BLEICHROEDER LP
Shares:1.14M
Value:$1.03M
ARMISTICE CAPITAL, LLC
Shares:978.19K
Value:$884.77K
CITIGROUP INC
Shares:581.12K
Value:$525.62K
Summary
Showing Top 3 of 53